Roche's chief medical officer, Levi Garraway. Roche has thrown down the gauntlet to Amgen and Bristol Myers Squibb with new ...

For the first time, children in the US as young as two with the blood disorders sickle cell disease and beta thalassaemia are ...

The agency, consultancy, and investor segments saw a wave of senior-level appointments across April and May, as organisations ...

AstraZeneca has returned to China's CSPC Pharma to fill its R&D pipeline, reaching a new agreement to develop drugs for ...

HHS acknowledged in a statement on Operation Trailblazer that "a growing share of early-stage clinical research has moved ...

As the US relaxes an export ban on Anthropic's advanced AI tools, the company formally launched Claude Science, an AI ...

Orca Bio has become a commercial-stage company with the FDA approval of Tregzi, a cell-based immunotherapy designed to ...

Sanofi is preparing to expand the use of its Pompe therapy Nexviazyme, currently approved only for late-onset cases of the ...

Eli Lilly's LillyDirect sales channel, which has become an important driver of sales of its weight-loss therapies in the US, ...

At its latest R&D update, Moderna revealed a move into the pioneering in vivo CAR-T category, adding another treatment class ...

Point-of-care (POC) healthcare marketing is on the rise, experiencing 171% revenue growth since 2019 to surpass $803 million ...

French pharma company Ipsen has agreed to buy cancer biotech Kartos Therapeutics of the US for $450 million upfront, gaining ...